Loading...
Prostate cancer often has a protracted natural history, regardless of treatment. Since the 1980s, when prostate-specific antigen (PSA)-based screening became widely implemented, rising PSA levels have increasingly been used as surrogate markers of treatment failure, even though this measure correlates poorly with prostate cancer–specific mortality.
To develop a nomogram for predicting disease-specific mortality after radical prostatectomy, investigators retrospectively studied a multicenter cohort of 12,677 men who had undergone this procedure in the U.S. from 1987 through 2005. Patients were divided into a modeling cohort — in which multiple factors (including Gleason grade, PSA levels, and clinical variables) were used to develop the nomog…